암 백신 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of cancer vaccines Market

The global cancer vaccines market was valued at USD 13.86 billion in 2025 and is projected to grow to USD 15.93 billion in 2026, reaching USD 62.93 billion by 2034, registering a strong CAGR of 18.74% during the forecast period (2026-2034). North America dominated the market with a 35.97% share in 2025, supported by advanced healthcare infrastructure and high cancer prevalence.

Cancer continues to be a major global health burden, with rising incidence rates driving demand for preventive and therapeutic vaccines. Increasing awareness, improved diagnostics, and expanding immunization programs are further strengthening market growth.

Market Trends

A key trend shaping the market is the rising investment in research and development (R&D) for preventive and therapeutic cancer vaccines. Pharmaceutical and biotech companies are focusing on developing innovative vaccines using advanced technologies such as mRNA platforms, AI-based modeling, and genomic sequencing.

Additionally, collaborations between research institutes and companies are accelerating innovation. Increasing clinical trials for vaccines targeting conditions such as Lynch Syndrome and melanoma are further boosting market expansion.

Market Growth Factors

Increasing Cancer Incidence

The growing global burden of cancer is a major driver for market growth. Rising cases of cervical, lung, breast, and prostate cancers are increasing demand for preventive vaccines. Factors such as smoking, pollution, unhealthy lifestyle, and infections like HPV contribute significantly to cancer prevalence.

Government Initiatives and Immunization Programs

Governments and global organizations are promoting vaccination programs to reduce cancer incidence. Public health campaigns and HPV vaccination initiatives are improving awareness and adoption, especially in developing countries.

Technological Advancements

Innovations in personalized vaccines, neoantigen targeting, and immunotherapy are enhancing treatment outcomes. Integration of AI and biotechnology is enabling faster development of highly targeted cancer vaccines.

Restraining Factors

Despite strong growth, the market faces certain limitations. One major challenge is the rise of personalized medicine, which offers targeted therapies with better outcomes. These treatments reduce reliance on traditional vaccines.

Additionally, limited approvals for certain cancer types and high development costs also restrict widespread adoption of cancer vaccines.

Segmentation Analysis

By Type

The preventive segment dominated the market, accounting for 91.52% share in 2026, driven by increased HPV vaccine adoption and growing focus on cancer prevention. The therapeutic segment is expected to grow at a faster rate due to ongoing research and product development.

By Technology

The molecular-based segment held the largest share (92.27% in 2026) due to advancements in recombinant and mRNA vaccines. Vector-based and cell-based technologies are also gaining traction.

By Indication

The cervical cancer segment dominated the market (88.89% in 2026) due to rising HPV infections and increasing awareness. Other segments such as lung, prostate, and bladder cancer are expected to grow steadily.

By Distribution Channel

The hospital segment led the market with a 55.39% share in 2026, supported by high patient visits and better vaccine accessibility. Government supply channels are also expanding due to mass immunization initiatives.

Regional Insights

North America

North America accounted for USD 4.99 billion in 2025 and is expected to reach USD 5.71 billion in 2026. Growth is driven by high cancer incidence, strong R&D ecosystem, and presence of leading companies.

Europe

Europe held USD 4.08 billion in 2025, supported by rising investments in clinical trials and vaccine development. Countries such as Germany, the UK, and France are key contributors.

Asia Pacific

Asia Pacific reached USD 4.12 billion in 2025 and is projected to grow significantly due to increasing awareness, government initiatives, and expanding healthcare infrastructure. Countries like China, India, and Japan are leading growth.

Latin America & Middle East & Africa

These regions showed moderate growth, with USD 0.39 billion and USD 0.28 billion respectively in 2025, driven by rising cancer prevalence and improving access to healthcare services.

Competitive Landscape

The market is highly competitive with key players such as Merck & Co., Inc., GlaxoSmithKline plc, Dendreon Pharmaceuticals LLC., and Serum Institute of India Pvt. Ltd. leading innovation.

Companies are focusing on strategic collaborations, acquisitions, and clinical trials to strengthen their market position. Increasing investments in manufacturing and distribution are also supporting global expansion.

Conclusion

The cancer vaccines market is poised for significant growth, driven by rising cancer incidence, technological advancements, and increasing global focus on preventive healthcare. With strong R&D pipelines, expanding immunization programs, and innovations such as mRNA and personalized vaccines, the market is expected to transform cancer treatment and prevention. Despite challenges such as high costs and competition from personalized therapies, continuous innovation and government support will ensure sustained market expansion through 2034.

Segmentation

By Type

• Preventive
• Therapeutic

By Technology

• Molecular-based
• Vector-based
• Cell-based

By Indication

• Cervical Cancer
• Bladder Cancer
• Prostate Cancer
• Lung Cancer
• Others

By Distribution Channel

• Hospitals
• Government & Organization Supply
• Others

By Region

• North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
  • France
  • Italy
  • Spain
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Different Cancers, by Key Countries, 2025
• 4.2. Overview of Regulatory Scenario by Key Countries/Regions
• 4.3. Pipeline Analysis, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.5. New Product Launches
• 4.6. Impact of COVID-19 on Global Cancer Vaccines Market

5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Preventive
  • 5.1.2. Therapeutic
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Molecular-based
  • 5.2.2. Vector-based
  • 5.2.3. Cell-based
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Cervical Cancer
  • 5.3.2. Bladder Cancer
  • 5.3.3. Prostate Cancer
  • 5.3.4. Lung Cancer
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospitals
  • 5.4.2. Government & Organization Supply
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Preventive
  • 6.1.2. Therapeutic
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Molecular-based
  • 6.2.2. Vector-based
  • 6.2.3. Cell-based
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Cervical Cancer
  • 6.3.2. Bladder Cancer
  • 6.3.3. Prostate Cancer
  • 6.3.4. Lung Cancer
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospitals
  • 6.4.2. Government & Organization Supply
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Preventive
  • 7.1.2. Therapeutic
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Molecular-based
  • 7.2.2. Vector-based
  • 7.2.3. Cell-based
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Cervical Cancer
  • 7.3.2. Bladder Cancer
  • 7.3.3. Prostate Cancer
  • 7.3.4. Lung Cancer
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospitals
  • 7.4.2. Government & Organization Supply
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. France
  • 7.5.2. Italy
  • 7.5.3. Spain
  • 7.5.4. U.K.
  • 7.5.5. Germany
  • 7.5.6. Rest of Europe

8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Preventive
  • 8.1.2. Therapeutic
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Molecular-based
  • 8.2.2. Vector-based
  • 8.2.3. Cell-based
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Cervical Cancer
  • 8.3.2. Bladder Cancer
  • 8.3.3. Prostate Cancer
  • 8.3.4. Lung Cancer
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospitals
  • 8.4.2. Government & Organization Supply
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Preventive
  • 9.1.2. Therapeutic
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Molecular-based
  • 9.2.2. Vector-based
  • 9.2.3. Cell-based
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Cervical Cancer
  • 9.3.2. Bladder Cancer
  • 9.3.3. Prostate Cancer
  • 9.3.4. Lung Cancer
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospitals
  • 9.4.2. Government & Organization Supply
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Preventive
  • 10.1.2. Therapeutic
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. Molecular-based
  • 10.2.2. Vector-based
  • 10.2.3. Cell-based
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Cervical Cancer
  • 10.3.2. Bladder Cancer
  • 10.3.3. Prostate Cancer
  • 10.3.4. Lung Cancer
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospitals
  • 10.4.2. Government & Organization Supply
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Dendreon Pharmaceuticals LLC.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Serum Institute of India Pvt. Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. GlaxoSmithKline plc
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Walvax Biotechnology Co., Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Synthaverse S.A.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Center of Molecular Immunology
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Ferring B.V.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Wantai BioPharm
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Dynavax Technologies Corporation
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)